share_log

AstraZeneca | 6-K: Astrazeneca to Acquire Fusion to Accelerate the Development of Next-Generation Radioconjugates to Treat Cancer

AstraZeneca | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

阿斯利康 | 6-K:外國發行人報告
SEC announcement ·  03/19 06:06
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息